Oksidiasemia

Oksidiasemia is a term used in some biomedical contexts to describe elevated levels of oxidized molecules in the blood, indicating systemic oxidative stress. Oxidation refers to chemical modification of lipids, proteins, and nucleic acids by reactive oxygen or nitrogen species. Oksidiasemia is not a single disease but a laboratory concept or biomarker used in research and sometimes in clinical discussions about diseases linked with oxidative damage.

Causes include increased production of reactive oxygen species due to inflammation, infection, ischemia-reperfusion injury, metabolic disorders such as diabetes, smoking, aging, and exposure to toxins, as well as reduced antioxidant defenses.

Measurement of oxidized species in blood uses several biomarkers, including malondialdehyde (MDA), F2-isoprostanes, advanced oxidation protein products (AOPP), and protein carbonyls. There is no universally accepted standard test for oksidiasemia, and values depend on assay, sample handling, and reference ranges.

Clinical relevance: Elevated oxidized biomarkers have been observed in cardiovascular disease, neurodegenerative disorders, diabetes complications, sepsis, and trauma, and in some studies correlate with disease severity or prognosis. However, the relationship is complex and not all studies show a direct causal link between oxidation and disease progression.

Management focuses on addressing underlying conditions and reducing oxidative stress where appropriate. Evidence for routine antioxidant supplementation is limited and variable; lifestyle measures such as diet rich in antioxidants, regular exercise, smoking cessation, and good glycemic control are commonly recommended.